Ventria Bioscience

Company type	Private company
Industry	Biotechnology
Founded	1993
Headquarters	Fort Collins, CO
Area served	United States
Products	Bioscience Products
Website	www.ventria.com

Ventria Bioscience is a biotech company with a focus on human nutrition and human therapeutics. The company was established in 1993 in Colorado.^[1] The company's core technology is a genetically modified crop-based protein production system (also called a "pharming" system) called ExpressTec.

ExpressTec uses self-pollinating crops such as rice and barley to minimize the risk of gene flow normally associated with transgenic plants. Plant-produced proteins also offer advantages for cell culture and bioprocessing use because they replace animal derived components, which have become unpopular due to concerns about prion contamination.^{[citation needed]}

Facilities

Ventria's corporate headquarters is in Denver, Colorado, with additional facilities in Kansas. On September 29, 2006, Kansas officials announced an agreement to bring Ventria’s new bioprocessing facility to Junction City, Kansas. Kansas Governor Kathleen Sebelius was very supportive of the agreement and was quoted as stating "I welcome Ventria Bioscience to Kansas and look forward to their contributions to the health of children worldwide."^[2] The effort to attract Ventria to Kansas involved a number of players, including Governor Kathleen Sebelius, Secretary of Agriculture Adrian Polansky, The Kansas Department of Commerce, Junction City and Geary County, Kansas Technology Enterprise Corporation (KTEC), KansasBIO, Kansas State University, and Kansas Farm Bureau.

Markets and products

As of 2012 Ventria is developing six therapeutic products:

• Human Health
  • VEN100 Recombinant human lactoferrin for antibiotic-associated diarrhea^[3]
  • VEN101 for Chemotherapy-Induced Diarrhea^[4]
  • VEN120 for Inflammatory Bowel Disease^[5]
  • VEN130 for Osteoporosis^[6]
  • VEN140 for Hepatic disease^[7]
  • VEN200 Optibumin Recombinant human albumin as a replacement for therapeutic human serum albumin^[8]

The company offers contract biomanufacturing services using its ExpressTec platform, and, through its subsidiary InVitria, sells a line of its proteins that it manufactures for the life sciences research market.^[9]

The company has conducted research in the field of zoonotic disease, specifically in lyme disease and rabies, with a goal of developing vaccines and offers some its recombinant proteins to life sciences researchers under a program called BioShare.^[10]